Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Titel:
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Auteur:
Wu, Yi-Long Zhou, Caicun Hu, Cheng-Ping Feng, Jifeng Lu, Shun Huang, Yunchao Li, Wei Hou, Mei Shi, Jian Hua Lee, Kye Young Xu, Chong-Rui Massey, Dan Kim, Miyoung Shi, Yang Geater, Sarayut L